...By stephen hansen, associate editor A third setback for the $5 billion Galapagos-Gilead deal will now...
...the partners turn their attention to another fibrosis candidate and a Toledo program that targets salt-inducible kinases.Galapagos N.V....
...billion deal that essentially gave Gilead Sciences Inc. (NASDAQ:GILD) ex-EU rights to nearly all of Galapagos’...

...after Jyseleca’s surprise setback at FDA, Gilead and Galapagos...
...the August complete response letter for Jyseleca filgotinib from Galapagos N.V....
...and Galapagos valuations for the time being.” Galapagos...

...gene editing and allogeneic cell therapies across a range of indications.Galapagos hits in IPFGLPG1205 from Galapagos N.V....
...HER1) – Epidermal growth factor receptorGPR84 – G protein-coupled receptor 84 BC Staff Alzumab, itolizumab (EQ001, anti-cd6, t1h) Equillium Biocon Moderna Bayer Galapagos Braeburn Genmab COVID-19 cov19count chs2020 cov19count...

...By Lauren Martz, Senior Editor Galapagos’ latest move to expand its early fibrosis pipeline, via a...
...the company access to a new fibrosis-blocking immune mechanism. Through the exclusive collaboration and licensing agreement, Galapagos N.V....
...million ($343 million) in development, regulatory and commercial milestones and tiered royalties up to low double-digits.Galapagos...

...By BC Staff EMA reviewing filgotinib for ulcerative colitisGilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG...
...Pharmaceuticals Inc. Cystic Fibrosis Foundation DBV Technologies S.A. European Medicines Agency (EMA) U.S. Food and Drug Administration (FDA) Gilead Sciences Inc. Galapagos N.V. Karyopharm...

...most notably with ADC developer Immunomedics, for near-term growth. Filgotinib, the centerpiece of an ongoing R&D collaboration with Galapagos N.V. (Euronext:GLPG...
...TACSTD2; EGP-1) – Tumor-associated calcium signal transducer 2 Virginia Li Gilead Sciences Inc. Jyseleca, filgotinib (GLPG0634, GS-6034)Gilead Sciences Inc.Galapagos N.V....

...therapies —Jyseleca filgotinib from Gilead and Galapagos...
...are close behind. Partners Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V....
...receptor 1 Stephen Hansen Jyseleca, filgotinib (GLPG0634, GS-6034) Gilead Sciences Inc. Galapagos N.V. Janus...

...first orders this week. Paul Bonanos Jyseleca, filgotinib (GLPG0634, GS-6034) D-0502 Galapagos N.V. InventisBio...

...By Virginia Li, Associate Editor Galapagos’ investors rewarded a clinical win on Friday for ziritaxestat, which...
...Detailed data will be presented at a future medical meeting.The readout is welcome news for Galapagos N.V....
...$1.1 billion in equity up front (see “Filgotinib Setback”; “Europe’s Next Big Biotech”). Despite Friday’s bump, Galapagos’...

...therapies received complete response letters from FDA: filgotinib, a JAK inhibitor from Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V....